Suppr超能文献

瘤内注射(131)I-chTNT 前进行射频消融可提高实体 VX2 肿瘤的肿瘤与正常组织比值。

Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.

机构信息

1 Department of Medical Ultrasonics, The First Affiliated Hospital, Sun Yat-Sen University , Guangzhou, China .

出版信息

Cancer Biother Radiopharm. 2013 Dec;28(10):725-30. doi: 10.1089/cbr.2012.1418. Epub 2013 Aug 21.

Abstract

PURPOSE

This study was aimed to investigate whether the tumor necrosis induced by radiofrequency ablation (RFA) can improve the ratio of tumor-to-normal tissue (T/NT) after intratumoral injection of (131)I-chTNT.

MATERIALS AND METHOD

Eighteen New Zealand rabbits bearing VX2 tumor on the thigh were randomly divided into two treatment groups (control group: intratumoral injection of (131)I-chTNT alone; RFA group: RFA + intratumoral injection of (131)I-chTNT 3 days after RFA) and each group was further divided into three subgroups I, II, and III (1-2 cm, 2-3 cm, and 3-4 cm in maximum diameter, respectively), by the tumor size. SPECT was performed to evaluate the T/NT on days 1, 8, and 15 after (131)I-chTNT injection.

RESULTS

After treatment, all rabbits underwent the SPECT whole-body scan and the T/NT was analyzed. The results showed that T/NT in the RFA group (55.45±41.83) was significantly higher compared with the control group (7.23±5.61) (F=18.89, p=0.001). Meanwhile, a linear ascending trend was found for T/NT in the RFA group along with the follow-up time (r=0.47, p=0.01). The tumor size or the dose of (131)I-TNT injection had no significant effect on the variation of T/NT in both groups (p>0.05).

CONCLUSION

RFA before intratumoral injection of (131)I-chTNT can dramatically improve T/NT, demonstrating the potential application of this combination therapy.

摘要

目的

本研究旨在探讨射频消融(RFA)诱导的肿瘤坏死是否能提高肿瘤内注射(131)I-chTNT 后肿瘤与正常组织(T/NT)的比值。

材料和方法

18 只新西兰兔大腿上长有 VX2 肿瘤,随机分为两组(对照组:单独肿瘤内注射(131)I-chTNT;RFA 组:RFA 后 3 天肿瘤内注射(131)I-chTNT),每组再按肿瘤最大直径分为三组(I、II、III 组,分别为 1-2cm、2-3cm 和 3-4cm)。SPECT 分别于注射(131)I-chTNT 后 1、8 和 15 天评估 T/NT。

结果

治疗后,所有兔子均行 SPECT 全身扫描,分析 T/NT。结果显示,RFA 组(55.45±41.83)的 T/NT 明显高于对照组(7.23±5.61)(F=18.89,p=0.001)。同时,RFA 组的 T/NT 随时间呈线性上升趋势(r=0.47,p=0.01)。两组肿瘤大小或(131)I-TNT 注射剂量对 T/NT 的变化均无显著影响(p>0.05)。

结论

肿瘤内注射(131)I-chTNT 前进行 RFA 可显著提高 T/NT,显示了这种联合治疗的潜在应用。

相似文献

本文引用的文献

2
Hepatocellular carcinoma.肝细胞癌。
Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20.
3
6
Tositumomab and iodine I 131 tositumomab (Bexaar).托西莫单抗和碘 131 托西莫单抗(Bexaar)。
AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8. doi: 10.3174/ajnr.A2593. Epub 2011 Mar 24.
7
Management of hepatocellular carcinoma: an update.肝细胞癌的管理:最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验